Clinical Trial Update: Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease [Phase 2]

View source ↗

Summary

A Phase II trial evaluated high-dose cyclophosphamide in patients with severe autoimmune hematologic disease. The study focused on autoimmune hemolytic anemia, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia
• Felty Syndrome
• Immune Thrombocytopenic Purpura

Drugs mentioned

• Cytoxan (cyclophosphamide) (cyclophosphamide)

Snippet

Sponsor: Johns Hopkins University | Conditions: Anemia, Hemolytic, Autoimmune, Felty Syndrome | Phase 2 | Status: COMPLETED